论文部分内容阅读
近期的研究显示,对于T_(1-2)N_0的局限性前列腺癌,局部治疗后的10年特异性生存率为90%。因此,治疗相关性不良反应发生率以及对生活质量的影响对治疗方法的选择有非常重要的作用。在前列腺癌的局部治疗中,永久性近距离放疗(BT)和外放疗(EBRT)以及两者联合应用是常用的治疗选择。研究数据显示,有近18.4%的低危前列腺癌患者选择BT,6.8%的患者选择EBRT治疗。推测2006年美国有近半数前列腺癌患者会选择放疗。BT治疗后尿瘘发生率约为0.3%～3.0%,EBRT治疗后尿瘘发生率为0～0.6%。但尿瘘的保守治疗效果不佳,大多需要手术治疗。作者
Recent studies have shown that for T_ (1-2) N_0 localized prostate cancer, the 10-year specific survival after topical treatment is 90%. Therefore, the incidence of treatment-related adverse events and the impact on quality of life play a very important role in the choice of treatment. In the local treatment of prostate cancer, permanent brachytherapy (BT) and external beam radiotherapy (EBRT) and the combination of the two is a commonly used treatment option. Data from the study showed that nearly 18.4% of patients with low-risk prostate cancer chose BT and 6.8% chose EBRT. Presumably in 2006 nearly half of the United States prostate cancer patients will choose to radiotherapy. The incidence of urinary fistula after BT treatment is about 0.3% ~ 3.0%, and the incidence of urinary fistula after EBRT treatment is 0 ~ 0.6%. However, conservative treatment of urinary fistula ineffective, most of them require surgery. Author